Form 8-K

8-K — Endovia Health Sciences, Inc.

Accession: 0001731122-26-001173

Filed: 2026-08-31

Period: 2026-08-31

CIK: 0001553788

SIC: 2080 (BEVERAGES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7903_8-k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7903_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7903_8-k.htm · Sequence: 1

false

0001553788

2026-08-31

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 31, 2026

ENDOVIA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-40471

34-1720075

(State or other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1112 N. Flagler Drive

Fort Lauderdale,

Florida

33304

(Address of principal executive offices)

(Zip Code)

Registrant’s

telephone number, including area code: (954) 648-7238

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act:

Title

of Each Class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, $0.001 par

value

SBEV

NYSE American LLC

Item 7.01 Regulation FD Disclosure

On August 31, 2026, Endovia Health Sciences, Inc.

(the “Company”) issued a press release announcing certain developments. A copy of the press release is furnished as Exhibit

99.1 of this Current Report on Form 8-K.

The information in this Item 7.01 (including Exhibit

99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)

or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of

the Company under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

Description

99.1

Press Release dated August 31, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of

the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

ENDOVIA HEALTH SCIENCES, INC.

Date: August 31, 2026

By:

/s/ Brady Cobb

Name:

Brady Cobb

Title:

Interim Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7903_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid

Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

Company views federal support for Schedule III as a significant evolution

in U.S. cannabinoid policy and an important step toward a durable regulatory framework for cannabinoid-based medicines and wellness products

Endovia expects to submit CannEpil® Z submission in the coming week

and request a pre-submission conference with the FDA

FORT LAUDERDALE, Fla. — August 31, 2026 — Endovia Health Sciences, Inc.

(NYSE American: EDVA) (“Endovia” or the “Company”), an emerging cannabinoid-based health sciences company, today

welcomed recent developments in the federal marijuana rescheduling process, including the position advanced by the federal government

during the Drug Enforcement Administration’s (“DEA”) recent administrative hearings supporting the proposed transfer

of marijuana from Schedule I to Schedule III of the Controlled Substances Act.

The Company believes the federal government’s affirmative support

for Schedule III represents a significant evolution in U.S. cannabinoid policy and provides an increasingly clear signal that the federal

government is moving toward a long-term regulatory framework that recognizes the medical potential of cannabinoids while maintaining appropriate

federal oversight.

“What we heard from the federal government during the DEA proceedings

represents a meaningful change in the direction of U.S. cannabinoid policy,” said Brady Cobb, Chairman and Chief Executive Officer

of Endovia Health Sciences. “For decades, Schedule I created an extraordinary disconnect between the rapidly expanding scientific

understanding of cannabinoids, state-regulated medical cannabis programs and federal policy. The federal government is now expressly advocating

for Schedule III and recognizing marijuana’s accepted medical use. We believe that is a significant moment.”

During the recent administrative proceedings, counsel for the federal government

supported the proposed transfer of marijuana to Schedule III and presented evidence intended to establish that marijuana has a currently

accepted medical use. These proceedings follow other recent federal actions reflecting an evolving approach to cannabinoid regulation,

medical use and research.

Endovia believes these developments could have important long-term implications

for cannabinoid research, pharmaceutical development and the broader state-regulated medical cannabis industry. If Schedule III is ultimately

finalized, the Company believes it could remove a significant historical federal impediment to cannabinoid research and development, facilitate

additional scientific and clinical investigation, and create a substantially more workable environment for cannabinoid formulations to

progress through established FDA regulatory pathways.

“For Endovia, the importance goes well beyond the cannabis industry,”

Cobb continued. “We believe the United States is moving toward a regulatory environment where cannabinoid formulations can increasingly

be evaluated like other potential therapeutic compounds—through science, research, clinical evidence and established FDA processes.

That is precisely where we have positioned Endovia.”

CannEpil® FDA Development Update

Against this evolving federal backdrop, Endovia continues to advance its

cannabinoid-based pharmaceutical development strategy, including the development of CannEpil®, its proprietary cannabinoid formulation.

The Company currently expects to submit a pre-submission conference with

the FDA to discuss the proposed regulatory and development pathway for CannEpil®.

The upcoming submission represents another step in Endovia’s strategy

to advance CannEpil® through an FDA-regulated pathway while simultaneously evaluating opportunities for the product across additional

indications and international markets.

“Our strategy is not dependent upon federal legalization of adult-use

cannabis. We are building a cannabinoid-based health sciences company designed around the emerging federal framework,” Cobb said.

“CannEpil is our first major asset within that strategy, and we expect to make our next FDA submission in the coming week and request

a pre-submission conference with the FDA. At the same time, we are evaluating additional cannabinoid-based formulations and working with

our capital partners to expand the resources available to execute on opportunities that may present.”

Expanding Endovia’s Cannabinoid-Based Pipeline

Endovia is also actively reviewing several additional cannabinoid-based

formulations and intellectual property opportunities for potential licensing, acquisition or strategic collaboration.

The Company’s evaluation is focused on opportunities that complement

its strategy of building a diversified cannabinoid-based health sciences platform centered around scientifically supported formulations,

established regulatory pathways and products capable of addressing meaningful unmet medical and wellness needs.

Endovia is concurrently working with its capital partners to finalize expanded

financing intended to support the Company’s cannabinoid-based development activities, potential licensing and acquisition opportunities,

and the continued expansion of its operations.

“The federal conversation is changing from whether cannabinoids have

legitimate medical potential to how cannabinoid products should be researched, regulated and responsibly brought to market,” Cobb

concluded. “We believe that shift strongly validates the strategy we have been building at Endovia.”

About CannEpil®

CannEpil® is a proprietary pharmaceutical-grade cannabinoid formulation

comprised of cannabidiol (CBD) and tetrahydrocannabinol (THC) isolates in an oral liquid formulation manufactured under European Union

Good Manufacturing Practice (EU-GMP) standards. Splash holds the exclusive global rights to develop and commercialize CannEpil® across

licensed fields of use, including veterinary therapeutics.

About Endovia Health Sciences

The Company has rebranded as Endovia Health Sciences (NYSE American:

EDVA), with a corporate name change and ticker symbol change effective on the NYSE American on August 24, 2026. The rebranding reflects

the Company’s evolution into a diversified cannabinoid-based health sciences platform focused on pharmaceutical commercialization,

FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage opportunities across pharmaceutical,

veterinary and consumer wellness markets.

Where Science Meets Cannabinoid Innovation

More Information

Endovia Health Sciences: endoviasciences.com

Contact Information

Endovia Health Sciences

investors@endoviasciences.com

Media Contact

Angela Gorman

AMWPR

angela@amwpr.com

917-348-0083

Forward-Looking Statements

This press release contains “forward-looking statements” within

the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding Endovia Health

Sciences, Inc.’s expectations, plans and objectives concerning the development, regulatory advancement and commercialization of

CannEpil® and other cannabinoid-based products; the timing, submission and potential outcomes of regulatory filings and interactions

with the U.S. Food and Drug Administration, including the Company’s anticipated Z submission and request for a pre-submission conference;

the potential impact of marijuana rescheduling and other changes in federal or state laws, regulations or enforcement policies relating

to cannabis, cannabinoids and cannabinoid-based products; the Company’s ability to identify, evaluate, license, acquire or develop

additional cannabinoid formulations, technologies or intellectual property; the availability, timing and terms of additional financing;

and the Company’s plans to expand its cannabinoid-based health sciences platform and operations.

These forward-looking statements are based on current expectations, estimates,

assumptions and projections and involve risks and uncertainties that could cause actual results, developments or events to differ materially

from those expressed or implied by such statements. Such risks and uncertainties include, among others, the timing, scope and ultimate

outcome of federal marijuana rescheduling proceedings; changes in applicable federal, state and international laws and regulations; the

timing and outcome of FDA and other regulatory submissions, meetings and reviews; the Company’s ability to successfully develop,

obtain regulatory approval for and commercialize CannEpil® or other product candidates; the Company’s ability to identify and

consummate licensing, acquisition or strategic transactions on acceptable terms; the availability of financing on acceptable terms, or

at all; the Company’s ability to execute its business strategy; and other risks and uncertainties. Additional risks are described

in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended

December 31, 2025, the Form S-1 filed on August 7, 2025, as amended, and the final prospectus filed pursuant to Rule 424(B)(3) on August

28, 2026.

Forward-looking statements can often be identified by words such as “anticipate,”

“believe,” “continue,” “could,” “expect,” “intend,” “may,” “plan,”

“potential,” “seek,” “should,” “will,” “would” and similar expressions, although

not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on these forward-looking

statements. Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company

undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events

or otherwise.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 31, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 31, 2026

Entity File Number

001-40471

Entity Registrant Name

ENDOVIA HEALTH SCIENCES, INC.

Entity Central Index Key

0001553788

Entity Tax Identification Number

34-1720075

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1112 N. Flagler Drive

Entity Address, City or Town

Fort Lauderdale

Entity Address, State or Province

Entity Address, Postal Zip Code

33304

City Area Code

(954)

Local Phone Number

648-7238

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par

value

Trading Symbol

SBEV

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration